Stockreport
Summit Therapeutics' (SMMT) CEO Glyn Edwards on Q4 2017 Results - Earnings Call Transcript [Seeking Alpha]
US:NASDAQ Investor Relations: summitplc.com/investors/investor-centre
PDF
Summit Therapeutics' (SMMT) CEO Glyn Edwards on Q4 2017 Results - Earnings Call Transcript
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | SMMT | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
SMMT alerts
SMMT alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting SUMMIT THERAPEUTICS PLC AMERICA news events
Weekly update
A roundup of the hottest topics
SMMT
NEWS
NEWS
- Summit Therapeutics (NASDAQ: SMMT) was given a new $20.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.[MarketBeat]
- Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018[GlobeNewswire]
- Award of Share Options and Restricted Stock Units[GlobeNewswire]
- Summit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 American Academy of Neurology Annual Meeting[GlobeNewswire]
- Summit Therapeutics (NASDAQ: SMMT) was upgraded by analysts at Zacks Investment Research from a "strong sell" rating to a "hold" rating.[MarketBeat]
- More
SMMT
SEC Filings
SEC Filings
- 4/24/18 - Form 6-K
- 4/13/18 - Form 20-F
- 4/11/18 - Form 6-K
- SMMT's page on the SEC website
- More